MalarVx, Inc. closely collaborates with  Stephan Kappe's malaria research program at Center for Infectious Disease Research (CIDR) and the Walter Reed Army Institute of Research (WRAIR). MalarVx scientists and engineers  to create an in vitro culture system for the Kappe Lab's attenuated P. falciparum parasite that can be used in the development of a genetically-attenuated whole parasite (GAP) vaccine. Together we are working to optimize the storage conditions for a whole parasite vaccine, and the optimal route of administration for maximum efficacy of the vaccine. MalarVx has licensed the rights to the in vitro culture process from WRAIR, and our scientist have continued to optimize and enhance the process as we automate the entire in vitro culture process.